ProPhase Labs explores crypto treasury strategy after shareholder approval

ProPhase Labs Inc. (NASDAQ: PRPH) announced it entered into an agreement for potential advisory services as the company evaluates options for allocating balance sheet resources, including possible investments in digital assets.

The biotech and consumer products company received shareholder approval for all proxy items at a September 9 special meeting, positioning it to advance its crypto treasury strategy. CEO and Chairman Ted Karkus stated the company cancelled its equity line of credit to avoid dilutive financing.

"We believe that we have significant underlying value in the Company, potentially multiples of the current market capitalization," Karkus said in the press release. "Therefore, we have no interest in a discounted, dilutive round of financing."

ProPhase indicated it is structuring the crypto treasury strategy to be accretive to current shareholders. The company expects to provide updates on its Crown Medical Collections initiatives, which could generate $50 million in cash, and developments in its BE-Smart esophageal cancer test.

The Uniondale, New York-based company operates in biotechnology, genomics and consumer products. ProPhase develops whole genome sequencing solutions, diagnostic tests and direct-to-consumer dietary supplements.

The announcement comes as the company continues evaluating various options for deploying its balance sheet resources while maintaining its commitment to preserving shareholder value.

You May Also Be Interested In

• Cosmos Health receives 180-day NASDAQ extension for bid price compliance
• Cosmos Health signs letter of intent to acquire Doc Pharma for $24M
• Diana Shipping urges Genco shareholders to vote against poison pill